In last trading session, Arcus Biosciences Inc (NYSE:RCUS) saw 4.73 million shares changing hands with its beta currently measuring 1.33. Company’s recent per share price level of $11.10 trading at $0.14 or 1.28% at ring of the bell on the day assigns it a market valuation of $1.02B. That closing price of RCUS’s stock is at a discount of -82.97% from its 52-week high price of $20.31 and is indicating a premium of 4.05% from its 52-week low price of $10.65.
For Arcus Biosciences Inc (RCUS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.58. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -1.2 in the current quarter.
Arcus Biosciences Inc (NYSE:RCUS) trade information
Upright in the green during last session for gaining 1.28%, in the last five days RCUS remained trading in the red while hitting it’s week-highest on Friday, 02/14/25 when the stock touched $11.10 price level, adding 17.72% to its value on the day. Arcus Biosciences Inc’s shares saw a change of -25.45% in year-to-date performance and have moved -7.27% in past 5-day. Arcus Biosciences Inc (NYSE:RCUS) showed a performance of -20.88% in past 30-days.
Wall Street analysts have assigned a consensus price target of 32 to the stock, which implies a rise of 65.31% to its current value. Analysts have been projecting 20 as a low price target for the stock while placing it at a high target of 46. It follows that stock’s current price would drop -80.18% in reaching the projected high whereas dropping to the targeted low would mean a loss of -80.18% for stock’s current value.
Arcus Biosciences Inc (RCUS) estimates and forecasts
This year revenue growth is estimated to rise 123.58% from the last financial year’s standing.
8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 29.38M for the same. And 6 analysts are in estimates of company making revenue of 41.81M in the next quarter. Company posted 31M and 145M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -23.70% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 17.81% while estimates for its earnings growth in next 5 years are of -1.18%.
Arcus Biosciences Inc (NYSE:RCUS)’s Major holders
BLACKROCK INC. is the top institutional holder at RCUS for having 9.76 million shares of worth $148.69 million. And as of 2024-06-30, it was holding 11.3261 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 5.26 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.099 of outstanding shares, having a total worth of $80.07 million.
